The Week in Review: Medical Device Company to IPO in Hong Kong

Trauson (Jiangsu) Holdings, an orthopedic products company, will stage a $98 million IPO in Hong Kong; Shandong Lukang Pharma will invest 3.5 billion RMB ($514 million) in a biomedical park; the Charles River Labs and WuXi PharmaTech tie-up could face regulatory opposition in China; Jiangsu Kanion Pharma bought an additional 33% stake in Nanxing Pharma; Johnson & Johnson is rumored to be involved in the most recent SFDA bribery scandal; Stallergenes announced a positive China Phase III trial of an asthma drug; Cellonis Biotech said its stem cell therapy shows promise as a diabetes treatment; and Renhuang Pharma will launch a TCM anti-depressant. More details… Stock Symbols: (SHEX: 600789) (NYSE: CRL) (NYSE: WX) (SHEX: 600557) (NYSE: JNJ) (OTCPK: RHGP)